Altogether, our study indicates that plasma YKL-40 may contribute to the diagnosis of CJD regardless of clinical heterogeneity, but it should be combined with other blood-based biomarkers to increase its diagnostic performance. The gene discussed is CHI3L1; the disease is Creutzfeldt Jacob disease.